News
Hosted on MSN1mon
AAIC25: Cognito neuromodulation therapy slows decline in ... - MSN
Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.
Cognito Therapeutics Announces Non-invasive Neuromodulation Therapy Delays Alzheimer’s Disease Progression- New peer-reviewed publication demonstrates that Spectris AD™ delays cognitive ...
About Cognito Therapeutics Cognito Therapeutics is a late clinical-stage medical device company pioneering neuroprotective therapies to address the unmet needs of patients living with CNS disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback